ACTRIMS/ECTRIMS 2020: Evobrutinib Has Sustained Activity and Good Tolerability in Open-Label Extension of Phase II Study in Relapsing Multiple Sclerosis
The drug is being compared head-to-head with teriflunomide in phase III trials
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.